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ABSTRACT
Objectives: The primary objective of the present study is to develop and evaluate tizanidine hydrochloride (TZ) solid lipid nanoparticles (SLNs) using 
solid lipids/triglycerides.
Methods: TZ SLNs were prepared by hot homogenization followed by ultrasonication technique. The prepared SLNs were characterized for drug 
content, entrapment and loading efficiency, particle size, zeta potential, polydispersity index (PDI), and in intro release kinetics.
Results: TZ SLNs were prepared. The particle size ranged from 49.7 to 523.7 nm. PDI of all formulations was good within the range of 0.189–0.487. 
The zeta potential of blank SLNs was −15.2 mV whereas drug-loaded SLNs showed zeta potential from −8.85 mV to −42.0 mV. Entrapment efficiency 
observed was in the range of 34.5–75.0%. The cumulative percentage release of TZ from different TZ nanoparticles varied from 35.28% to 83.98% 
depending on the drug-lipid ratio and the type of lipid and surfactant used. The release kinetic studies of optimized formulation showed that the 
release was first order and the release mechanism was non-Fickian type.
Conclusion: The prepared SLNs were able to sustain the drug release for 24 h, thus reducing dosing frequency and occurrence of side effects, thereby 
increasing the effectiveness of the drug.
Keywords: Tizanidine hydrochloride, Solid lipid nanoparticles, Hot homogenization, Ultrasonication, Fourier-transform infrared spectroscopy, 
In vitro drug release.
INTRODUCTION
Most of the people prefer oral route of administration as the major route 
of administration of pharmaceuticals having the advantage of being pain-
free, convenient to handle, and noninvasive [1]. However, the oral dosage 
form has several disadvantages. To overcome the disadvantages of the 
oral route of administration, many new powerful drug substances have 
been found due to new technologies employed in drug discovery. Solid 
lipid nanoparticles (SLNs) are the novel drug delivery system in which 
the active drug is incorporated into lipid carriers with the help of the 
stabilizers. They are solid colloids having the size in nanometers that range 
from 10 to 1000 nm at least in one dimension (generally 50–500 nm) [2]. 
SLNs combine the advantages of and simultaneously avoid the limitations 
of polymeric nanoparticles, fat emulsions, and liposomes [3].
Spasticity or increased tone is the tightness that patients report with 
passive movement of the limb. In more scientific language, spasticity 
is a motor disorder characterized by a velocity-dependent increase in 
the tonic stretch reflex [4]. Tizanidine is an agonist at α2-adrenergic 
receptor sites and presumably reduces spasticity by increasing 
presynaptic inhibition of motor neurons [5]. It acts mainly at the spinal 
cord level and is used for the symptomatic relief of spasticity associated 
with spinal cord injury or diseases or multiple sclerosis [6]. In the 
present study, we aim to develop tizanidine hydrochloride (TZ) loaded 




TZ was procured from the Swapnroop drug and pharmaceuticals, 
Ahmadabad. Tristearin (TS) was purchased from Sasol, Germany. 
Compritol 888 (CM) was obtained from Gattefosse, France. Glyceryl 
monostearate (GMS) was purchased from Research Lab Fine Chem 
Industries, Mumbai. Methanol, tween 80 (TW) and chloroform were 
purchased from SD Fine Chem Limited, Bengaluru. Soy lecithin (SL) and 
poloxamer 188 (PL) were obtained from HiMedia Laboratories Pvt., 
Ltd., Bengaluru. All the reagents used were of analytical grade.
Methods
Determination of λmax of TZ in phosphate buffer of pH 7.4
Accurately weighed the quantity of 10 mg of TZ was taken in 100 ml 
volumetric flask and was dissolved using phosphate buffer of pH 7.4 and 
the volume was made up to 100 ml with phosphate buffer of pH 7.4 to 
produce 100 µg/ml solutions. From the above stock solution, 10 μg/ml 
solutions were prepared and scanned between 200 nm and 400 nm 
by keeping phosphate buffer of pH 7.4 as blank [7]. The absorption 
maxima of 320 nm for TZ was obtained and used for further studies.
Preparation of calibration curve in phosphate buffer of pH-7.4
Accurately weighed quantity of 10 mg of TZ was taken in 100 ml 
volumetric flask and was dissolved in phosphate buffer of pH-7.4. 
Finally, the volume is made up to 100 ml with phosphate buffer of pH 7.4 
to produce 100 μg/ml solutions (stock solution-I). 0.2, 0.4, 0.6, 0.8, 
1.0, and 1.2 ml of stock solution-I were taken and transferred to 10 ml 
volumetric flasks, and volume was made up to 10 ml using phosphate 
buffer of pH 7.4 to get 2, 4, 6, 8, 10, and 12 μg/ml solutions, respectively. 
The absorbance of these solutions was determined in ultraviolet (UV)-
spectrophotometer at 320 nm, and the calibration curve was plotted [8].
Preparation of SLNs with TZ using lipids (CM, TS, and GMS)
SLNs were prepared using lipids (CM, TS, and GMS) and surfactants (TW 
and PL). Lipid was first melted by heating in a boiling tube and then SL 
and the drug was added to the lipid melt which was then heated to the 
temperature 5°C above the melting point of the lipid. Simultaneously, 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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surfactant (PL/TW) was dissolved in water in a test tube and heated 
to a temperature equal to that of the lipid phase. This aqueous phase 
was transferred to the lipid phase in small quantities by continuous 
homogenization. This mixture was homogenized at 20,000 rpm for 
5 min and then immediately placed in probe ultrasonicator at 75% 
amplitude for 30 min. Blank nanoparticles were prepared in a similar 
manner omitting the TZ in the preparation [9]. The composition of all 
formulations is listed in Table 1.
Evaluation of TZ SLNs
Fourier-transform infrared spectroscopy (FTIR)
Drug-polymer interactions were studied by FTIR spectroscopy. Pure 
drug, excipients, and physical mixture of drug and excipients were 
subjected to FTIR studies. The spectra were recorded by scanning in 
the wavelength of 400–4000 cm-1 in an FTIR spectrophotometer [10].
Differential scanning calorimetry (DSC)
The melting point of the pure drug and compatibility of the drug 
with the lipids were studied by the DSC [11]. It was performed using 
Shimadzu DSC-60 by keeping the samples in aluminum crucibles.
In vitro drug release study
In vitro drug release studies were carried out in Franz diffusion cell. 
2 ml of nanoparticles dispersion was placed in donor compartment, 
while the receiver compartment consists of 22 ml of diffusion medium, 
phosphate buffer pH of 7.4 maintained at 37±1°C in Franz diffusion 
cell. The rpm of the magnetic bead was maintained at 50 rpm. 2 ml 
of the sample was withdrawn at predetermined intervals, and the 
samples were analyzed for the drug content by UV-spectrophotometer 
at 320 nm. An equal volume of the diffusion medium was replaced 
in the receiver compartment after each withdrawal to maintain sink 
condition. Three trials were carried out for all formulations. From the 
data obtained, the percentage cumulative drug release was calculated 
and plotted against the function of time to study the pattern of drug 
release [11].
Drug content
About 0.2 ml of drug-loaded SLNs was added into 5 ml of methanol 
in the centrifuge tube. The solution was vortexed for 10 min and then 
centrifuged at 5000 rpm for 30 min. The supernatant was collected. The 
drug content in the supernatant was analyzed by UV-spectrophotometer 
for TZ at 319 nm [11].
Drug content was calculated using the following formula.
Practical amount of drug obtained% Drug content = ×100
Theoretical amount of drug
Percentage drug entrapment efficiency
About 2 ml of SLNs loaded with TZ was placed in the outer chamber 
of the Centrisart device, and the sample recovery chamber was placed 
Table 1: Composition of TZ loaded SLNs containing different lipids and surfactants
Formulation code Formulation no. TZ mg CM mg TS mg GMS mg TW mg PL mg SL mg DW ml
TZ-SLN-CM-TW25 F1 10 50 - - 25 - 25 10
TZ-SLN-CM-PL25 F2 10 50 - - - 25 25 10
TZ-SLN-CM-TW50 F3 10 100 - - 50 - 50 10
TZ-SLN-CM-TW100 F4 10 200 - - 100 - 100 10
TZ-SLN-CM-TW75 F5 10 150 - - 75 - 75 10
TZ-SLN-CM-PL75 F6 10 150 - - - 75 75 10
TZ-SLN-TS-TW75 F7 10 - 150 - 75 - 75 10
TZ-SLN-TS-PL75 F8 10 - 150 - - 75 75 10
TZ-SLN-GMS-TW75 F9 10 - - 150 75 - 75 10
TZ-SLN-GMS-PL75 F10 10 - - 150 - 75 75 10
TZ-SLN-TS-PL75 F11 - - 150 - - 75 75 10
*F11 is a blank formulation. TZ: Tizanidine hydrochloride, CM: Compritol, TS: Tristearin, GMS: Glyceryl monostearate, TW: Tween, PL: Poloxamer, SL: Soy lecithin
Table 2: Interpretation of Fourier-transform infrared spectroscopy studies
Compound Name Type of vibration Characteristic absorption (cm-1) Observed peak (cm-1)
TZ Secondary amine N-H stretch 3100–3500 3246.31
Aromatic C-H stretch 3000–3100 3074.63
C=C aromatic ring stretch 1600 and 1475 1606.76 and 1473.66
Secondary amine C-N stretch 1100–1300 1188.19
Aromatic C-Cl stretch 1035–1100 1068.6
Ring bending Strong peak near 700 709.83
TZ and tristearin Secondary amine N-H stretch 3100–3500 3244.38
Aromatic C-H stretch 3000–3100 3074.63
C=C aromatic ring stretch 1600 and 1475 1606.76 and 1465.95
Secondary amine C-N stretch 1100–1300 1174.69
Aromatic C-Cl stretch 1035–1100 1068.6
Ring bending Strong peak near 700 709.83
TZ and Compritol Secondary amine N-H stretch 3100–3500 3246.31
Aromatic C-H stretch 3000–3100 3074.63
C=C aromatic ring stretch 1600 and 1475 1606.76 and 1469.81
Secondary amine C-N stretch 1100–1300 1192.05
Aromatic C-Cl stretch 1035–1100 1068.6
Ring bending Strong peak near 700 711.76
TZ and glyceryl monostearate Secondary amine N-H stretch 3100–3500 3246.31
Aromatic C-H stretch 3000–3100 3074.63
C=C aromatic ring stretch 1600 and 1475 1606.76 and 1471.74
Secondary amine C-N stretch 1100–1300 1182.4
Aromatic C-Cl stretch 1035–1100 1068.6
Ring bending Strong peak near 700 709.83
TZ: Tizanidine hydrochloride
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Fig. 1: Fourier-transform infrared spectroscopy spectra of (a) tizanidine hydrochloride, (b) physical mixture of drug and Compritol, 





on the top of the sample. The unit was centrifuged at 5000 rpm for 
20 min. The SLNs along with the encapsulated drug remained in the 
outer chamber, and the aqueous phase was moved into the sample 
recovery chamber through filter membrane (molecular weight cutoff 
20,000 Daltons). The resulting aqueous phase was analyzed by UV-
spectrophotometer for TZ at 320 nm. The entrapment efficiency was 
calculated using the following relationship [12].
Total amt of drug
amt of drug in aq. phase% Entrapment efficiency = ×100
Total amt of drug

Particle size analysis
The particle size was determined by dynamic light scattering (DLS), 
using a Malvern System, with vertically polarized light supplied by 
an argon-ion laser (Cyonics) operated at 40 mW. Experiments were 
performed at a temperature of 25.0±0.1°C at a measuring angle of 90° 
to the incident beam [13].
Zeta potential
Zeta potential was measured using Malvern Zetasizer. Nanoparticles 
were diluted with distilled water and placed in a clear disposable zeta 
cell at 25°C. The sample was subjected to three zeta runs to determine 
both size and potential [14].
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Fig. 3: Standard graph of tizanidine hydrochloride in phosphate 
buffer of pH −7.4
Polydispersity index (PDI)
In light scattering, the term polydispersity and % polydispersity are 
derived from the PDI; a parameter calculated from a cumulants analysis 
of the DLS-measured intensity autocorrelation function. Particle 
size, zeta potential, and PDI are determined by the same instrument, 
i.e., Malvern Zetasizer [14].
Kinetic modeling of drug dissolution profiles [15]
The results of in vitro release profile obtained for all the formulations 
were plotted in models of data treatment and are as follows:
1. Zero-order kinetic model – cumulative % drug released versus time
2. First-order kinetic model – log cumulative percentage drug remaining 
versus time
3. Higuchi’s model – cumulative percentage drug released versus square 
root of time
4. Korsmeyer equation/Peppas model – log cumulative percentage 
drug released versus log time.
RESULTS AND DISCUSSION
Preformulation studies
Drug-polymer interaction study by FTIR spectrophotometer
The FTIR was performed for the drug (TZ), lipids (CM, TS, and GMS), 
and physical mixture of drug and lipids (TZ and CM, TZ and TS, and TZ 
and GMS). Fig. 1 shows the FTIR spectra of pure drug and the mixture 
of drug and lipids. Interpretation of the spectrum is shown in Table 2. 
The spectrum shows that there was no interaction between the drug 
and the lipid.
Fig. 2: Differential scanning calorimetry thermogram of (a) tizanidine hydrochloride, (b) physical mixture of drug and Compritol, 
(c) a physical mixture of drug and tristearin
a b
c
Table 3: Percentage of cumulative drug release of F1–F4 
formulations (n=3)
Time h Percentage of cumulative drug release
F1 F2 F3 F4
0.5 13.45±1.2 17.2±2.81 17.29±2.37 10.9±2.49
1.0 17.07±0.5 25.39±1.18 28.95±1.79 13.49±1.98
1.5 37.65±1.3 47.89±1.73 38.6±1.81 13.53±3.07
2.0 52.21±2.4 62.14±2.71 43.5±3.81 14.63±2.18
3.0 68.87±1.8 68.19±3.91 53.1±2.73 18.71±1.46
4.0 71.01±2.1 - 61.8±3.45 21.19±2.85
5.0 - - 69.25±2.49 25.74±3.45
6.0 - - 72.1±1.87 28.13±1.09
12.0 - - - 32.87±2.75
24.0 - - - 35.28±1.25
*F1, F2, F3 formulations showed a decrease in % CDR after 4, 3, and 6 h of 
diffusion, respectively
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Table 5: Entrapment efficiency and drug content of all formulations
F. No. Formulation code Amount of tizanidine hydrochloride Entrapment 
efficiency (%)
The drug content 
in percentageIn aqueous phase (mg) In lipid phase (mg)
F1 TZ-SLN-CM-TW25 6.55 3.45 34.50 84.50
F2 TZ-SLN-CM-PL25 6.18 3.82 38.20 88.32
F3 TZ-SLN-CM-TW50 6.42 3.58 35.80 79.20
F4 TZ-SLN-CM-TW100 4.35 5.65 56.50 94.35
F5 TZ-SLN-CM-TW75 2.88 7.12 71.20 80.40
F6 TZ-SLN-CM-PL75 3.42 6.58 65.80 91.76
F7 TZ-SLN-TS-TW75 3.18 6.82 68.20 96.12
F8 TZ-SLN-TS-PL75 2.77 7.23 72.30 98.71
F9 TZ-SLN-GMS-TW75 2.72 7.28 72.80 97.49
F10 TZ-SLN-GMS-PL75 2.50 7.50 75.00 96.85
TZ: Tizanidine hydrochloride, SLN: Solid lipid nanoparticle, GMS: Glyceryl monostearate, TW: Tween, PL: Poloxamer
Fig. 4: Size distribution profile of F8 formulation
Fig. 5: The zeta potential of F8 formulation
DSC studies
The thermal measurement of pure TZ and physical mixture of TZ and 
CM, TZ and TS were carried out using DSC. The pure drug TZ showed 
a peak at 294.3°C. In a physical mixture of TZ and CM, TZ showed a 
peak at 289.47°C. In a physical mixture of TZ and TS, TZ showed a peak 
at 295.31°C. It shows that the drug is stable with different lipids at 
different conditions. (Fig. 2 shows the DSC curve of pure drug and the 
mixture of drug and TS).
Preparation of standard graph of TZ in phosphate buffer of pH-7.4
Calibration curve of TZ was determined using a phosphate buffer of 
pH 7.4 at 320 nm. The regression was found to be 0.9996 (Fig. 3 shows 
the standard graph).
Release studies
The drug release from the nanoparticles was studied by Franz diffusion 
method. The cumulative percentage release of TZ from different 
TZ nanoparticles varied from 35.28% to 83.98% depending on the 
drug, surfactant, and the type of lipid used. Tables 3 and 4 show the 
percentage of cumulative drug release of all the formulations.
The experiment showed that the drug release from F1 to F4 formulations 
was not sustained for 24 h and formulations containing 150 mg of lipid 
sustained the drug release for 24 h and showed maximum drug release.
Entrapment efficiency and drug content
The entrapment efficiency of TZ loaded SLNs was determined by 
measuring the concentration of un-entrapped drug in an aqueous 
medium by centrifugation method using Centrisart device. The 
formulations containing 150 mg of lipid showed good entrapment 
efficiency. Results of entrapment efficiency and drug content are 
mentioned in Table 5.
Table 4: Percentage of cumulative drug release of F5–F10 formulations for 24 h (n=3)
Time in h Percentage of cumulative drug release
F5 F6 F7 F8 F9 F10
0.5 9.63±1.56 13.04±0.69 9.96±0.42 8.18±2.17 13.75±2.60 17.65±2.80
1.0 14.21±1.41 20.93±0.87 13.57±1.20 11.47±1.98 22.14±2.66 26.48±1.58
1.5 18.25±0.85 27.07±1.87 19.98±1.57 14.39±3.14 29.78±3.03 32.55±3.45
2.0 20.94±0.89 31.23±1.58 26.74±2.75 20.09±3.46 35.42±3.28 37.48±4.33
3.0 27.30±1.30 37.97±1.53 37.05±3.40 27.64±1.85 44.09±4.28 42.85±2.75
4.0 34.13±1.47 45.40±2.40 42.01±1.59 34.86±2.45 50.33±3.07 50.90±0.80
5.0 41.55±1.19 49.92±3.93 47.25±2.19 38.79±1.92 55.02±2.69 56.45±2.20
6.0 45.45±0.45 55.27±3.57 52.47±3.02 41.96±0.58 61.16±4.27 75.62±1.18
12.0 61.21±1.51 78.13±1.52 69.68±2.15 63.79±3.14 66.14±5.09 78.15±1.55
24.0 69.46±3.03 82.28±1.42 74.33±1.71 76.47±1.56 68.45±3.84 83.98±4.93
*F10 formulation showed the highest % CDR and F9 formulation showed the lowest % CDR
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Fig. 6: (a) Zero-order kinetics model of optimized formulation F8, (b) first-order kinetics model of optimized formulation F8, (c) Higuchi 
model of optimized formulation F8, (d) Peppas model of optimized formulation F8
Table 6: The particle size, polydispersity index, and zeta potential of the formulations
Formulation No. Formulation code Particle size (nm) PDI Zeta potential (mV)
F5 TZ-SLN-CM-TW75 433.90 0.189 −22.60
F6 TZ-SLN-CM-PL75 523.70 0.487 −37.40
F7 TZ-SLN-TS-TW75 49.70 0.204 −8.85
F8 TZ-SLN-TS-PL75 119.70 0.256 −23.90
F9 TZ-SLN-GMS-TW75 97.67 0.278 −30.70
F10 TZ-SLN-GMS-PL75 133.00 0.279 −42.00
F11 TZ-SLN-TS-PL75 108.00 0.408 −15.20
TZ: Tizanidine hydrochloride, SLN: Solid lipid nanoparticle, GMS: Glyceryl monostearate, TW: Tween, PL: Poloxamer
a b
c d
Table 7: The regression values of the tizanidine hydrochloride loaded SLNs
Formulation No. Formulation code Regression factor Peppas model
Zero-order First-order Higuchi model R2 n value
F5 TZ-SLN-CM-TW75 0.8095 0.9026 0.9463 0.9748 0.5493
F6 TZ-SLN-CM-PL75 0.7802 0.8917 0.9309 0.9692 0.4926
F7 TZ-SLN-TS-TW75 0.7341 0.8529 0.9036 0.9412 0.5699
F8 TZ-SLN-TS-PL75 0.862 0.9603 0.9724 0.9766 0.6277
F9 TZ-SLN-GMS-TW75 0.5712 0.6713 0.7823 0.8896 0.4279
F10 TZ-SLN-GMS-PL75 0.6701 0.7928 0.8473 0.939 0.4261
*R2 is the regression factor. TZ: Tizanidine hydrochloride, SLNs: Solid lipid nanoparticles, GMS: Glyceryl monostearate, TW: Tween, PL: Poloxamer
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the occurrence of side effects, improve bioavailability and increase the 
effectiveness of the drug.
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Among 10 formulations, the % cumulative drug release of F1, F2, F3, 
and F4 formulations in 24 h was not remarkable, and the entrapment 
efficiency was found to be very low. Hence, these formulations are 
eliminated from further studies such as particle size analysis, zeta 
potential, PDI, and release kinetics.
Characterization of nanoparticles
Particle size and zeta potential
Particle size analysis of the TZ SLNs was performed by the Malvern 
System.
Zeta potential measures the charge on the particles. It allows prediction 
about the storage stability of colloidal dispersion because of repulsion 
between the particles. Malvern Zetasizer is the most widely used 
instrument for the measurement of zeta potential. Table 6 shows the 
particle size, PDI and zeta potential of F5–F11 formulations including 
blank formulation. Figs. 4 and 5 show the particle size distribution and 
zeta potential of F8 formulation (optimized), respectively.
Release kinetics
Data obtained from in vitro release studies were fitted to various 
kinetic equations such as zero-order, first-order, Higuchi model, and 
Korsmeyer-Peppas model. A model processing of the in vitro release 
for F5–F10 formulations is tabulated below. The regression values of the 
formulations are listed in Table 7. The kinetic models of F8 formulation 
are shown in Fig. 6.
CONCLUSION
In this study, an attempt was made to formulate TZ SLNs using CM, 
TS, and GMS as carrier matrices, TW and PL as surfactants, SL as 
a stabilizer. FTIR and DSC studies were carried out to find out the 
possible interaction between the selected drug and lipids (CM, TS, and 
GMS). It revealed that there was no interaction between the selected 
drug and lipids.
TZ SLNs were prepared by hot homogenization technique. The 
method was able to produce nanoparticles of acceptable range and 
stability. All the formulations from F5 to F10 showed high entrapment 
efficiencies. SLNs were developed by taking three different types of 
lipids and with two different types of surfactants. Among all batches, 
in case of TZ_SLN_TS_CL75, lipid and surfactant were optimized after 
considering their particle size, zeta potential, and in vitro drug release 
profile.
Size, PDI, and zeta potential of F5–F10 formulations developed were in 
the acceptable and suitable range. The average entrapment efficiency of 
F5–F10 formulations was found to >70%. The release kinetics revealed 
that the drug release follows first-order kinetics. The release from TZ 
nanoparticles from the Korsmeyer-Peppas equation indicates that the 
release mechanism was non-Fickian. Based on the observations, it 
can be concluded that the formulated lipid nanoparticulate delivery 
system of TZ using widely accepted and physiologically safe lipids were 
capable of exhibiting sustained release properties for 24 h. They may 
be thus used to reduce the frequency of dosing, thereby minimizing 
